☆ 4.7 Meeting Abstract

Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL)

BLOOD (2018)

评价这篇论文

主要评分表示论文的整体质量水平。次要评分独立反映论文的优点或缺点。

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

© Peeref 2019-2024. All rights reserved.